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based on global quantitative real-time PCR
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Abstract
MicroRNAs (miRNAs) are small noncoding RNAs (18-25 nucleotides) that regulate gene expression at the post-
transcriptional level. Recent studies have demonstrated the presence of miRNAs in the blood circulation.
Deregulation of miRNAs in serum or plasma has been associated with many diseases including cancers and
cardiovascular diseases, suggesting the possible use of miRNAs as diagnostic biomarkers. However, the detection of
the small amount of miRNAs found in serum or plasma requires a method with high sensitivity and accuracy.
Therefore, the current study describes polymerase chain reaction (PCR)-based methods for measuring circulating
miRNAs. Briefly, the procedure involves four major steps: (1) sample collection and preparation; (2) global miRNAs
profiling using quantitative real-time PCR (qRT-PCR); (3) data normalization and analysis; and (4) selection and
validation of miRNA biomarkers. In conclusion, qRT-PCR is a promising method for profiling of circulating miRNAs
as biomarkers.
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Background
MicroRNAs (miRNAs), a class of 18 to 25 noncoding
nucleotides, are capable of regulating gene expression
through messenger RNA degradation or translational
repression and are involved in various biological pro-
cesses, such as proliferation, differentiation, develop-
ment, and apoptosis [1,2]. Recently, the presence of
miRNAs in the blood circulation has been reported [3].
Interestingly, deregulation of circulating miRNAs has
been associated with a variety of human diseases,
including cancer [4,5] and cardiovascular diseases [6,7],
indicating that miRNAs could be used as biomarkers for
cancer and other diseases.
Several methods, such as northern blot [8], bead-based
flow cytometry [9], microarray [10,11], quantitative real-
time PCR (qRT-PCR) [12-14], and deep sequencing
[15,16] have been developed to measure miRNA expres-
sion [17]. Of these methods, qRT-PCR is superior due to
its high sensitivity, specificity and reproducibility. While
other methods, such as microarray, require a larger
amount of RNA sample (usually more than 1 μg), qRT-
PCR requires less RNA input, where even as little as a
single cell can be used for profiling [18,19]. Since the
expression levels of circulating miRNAs are very low,
qRT-PCR is well adapted for analyzing circulating miR-
NAs profiles because of its sensitivity. In addition,
approximately 1,900 mature miRNAs have been found in
human genome (miRbase 18, released on November 3,
2011) [20]. As qRT-PCR is easily adapted to 384-well
plates, it is possible to carry out high-throughput screen-
ing. Here, we describe a procedure for the identification
of circulating miRNA biomarkers by qRT-PCR profiling
that is composed of four steps: (1) sample collection and
preparation; (2) global miRNA profiling using qRT-PCR;
(3) data normalization and analysis; (4) selection and vali-
dation of miRNA biomarker(s).
Step 1: Sample collection and preparation
Blood samples can be collected after obtaining the
approval of relevant ethics committees and informed
consents of donors. All information collected from
blood donors, including gender, age, disease grade,
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symptom, should be recorded. In general, at least tens
or hundreds of blood samples should be collected from
both pathological and healthy control groups in order to
acquire statistically significant data. To reduce costs at
the initial screening step, a pooled sample derived from
a number of individual specimens (for example, a mix-
ture of 10 to 20 specimens) can be used. Subsequently,
the candidate miRNA biomarkers can be further vali-
dated with a larger number of samples (> 100) to obtain
reliable results [21].
Both serum and plasma are appropriate for the detec-
tion of circulating miRNA. However, serum may be pre-
ferable to plasma due to the following reasons. First,
serum is easier to obtain from clinical sample repositories
compared to plasma. Second, plasma is more likely con-
taminated with platelets and erythrocytes [22]. Finally,
some anticoagulants used in plasma collection, such as
heparin, inhibit the efficiency of reverse transcription
and/or PCR, whereas ethylenediaminetetraacetic acid
(EDTA) and citrate are acceptable [23]. It is notable that
hemocytolysis during sample collection should be
avoided since the products interfere with circulating
miRNA quantification. To isolate serum/plasma, blood
samples are centrifuged at 3,000 × g for 10 min at 4°C or
room temperature. Centrifugation of the serum/plasma
can be performed once again at 15,000 × g to remove cell
debris [24]. Serum/plasma can be subjected to RNA puri-
fication immediately after centrifugation or stored at
-80°C, and these procedures should be kept consistent
throughout the study to reduce technical variation.
The purification of miRNAs from serum/plasma is dif-
ficult because very little amount of miRNAs exist in
these samples. In addition, serum/plasma contains
numerous inhibitors possibly contaminating the purified
RNA that could interfere with subsequent enzymatic
reactions. The efficiency of circulating miRNA purifica-
tion can be monitored by using a heterogenous spike-in
RNA, such as synthetic Caenorhabditis elegans miRNA
(cel-miRNA), which can be added following the mixing
of denaturing reagents.
Two specialized types of reagents have been developed
for the purification of circulating RNA. The first type is
Trizol LS reagent (Invitrogen) or Tri-Reagent BD (Mole-
cular Research Center). After incubation with these dena-
turing reagents and extraction with phenol/chloroform,
inhibiting factors in serum/plasma are removed effec-
tively. Total RNA is then precipitated with ethanol or iso-
propanol. Higher concentrations of RNA can be obtained
using less RNase-free water, which is an advantage of this
procedure. However, technical variation usually exists
due to the slight loss of RNA during washing and dissol-
ving steps. Moreover, the operation is laborious for pro-
cessing large numbers of clinical samples mainly due to
the precipitation procedure. In contrast, kits using a
column-binding strategy, such as miRNeasy (QIAGEN)
and mirVana PARIS kits (Ambion), may provide better
reproducibility and easier operation. By properly regulat-
ing the RNA affinity with ethanol on a solid support such
as silica or glass-fiber, small RNAs < 200 nucleotides can
bind to the column and then be eluted with RNase-free
water. The mirVana PARIS kit is preferred since it
applies an equal volume of denaturing reagent with
serum/plasma sample, significantly reducing the volume
of reagent used per sample and enhancing the efficiency
of RNA purification.
Generally, the concentration of total RNA purified
from serum/plasma can be measured using specific
equipment, for example the NanoDrop spectrophot-
ometer (NanoDrop Technologies), and is usually < 50
ng/uL [25].
Step 2: Global miRNA profiling using qRT-PCR
Following RNA purification, cDNA synthesis and subse-
quent miRNA profiling can be carried out by qRT-PCR.
Despite remarkable sensitivity and specificity of qRT-
PCR method, there are challenges for using this method
to analyze miRNA profiles due to the following reasons:
(1) miRNAs are too short to provide enough sequence
for primer design; (2) many miRNAs are highly con-
served in sequence; (3) there are multiple forms of miR-
NAs, including primary transcript (pri-miRNA), miRNA
precursor (pre-miRNA), and mature miRNA, therefore, it
requires outstanding specificity to recognize the mature
miRNAs. At present, there are two qRT-PCR methods
for miRNA expression analyses, the stem-loop method
and the poly(A) method.
The stem-loop method that uses an elaborately
designed stem-loop reverse transcription (RT) primer
for synthesizing the cDNA of miRNAs, is the most
extensively used approach for miRNA quantification
(Table 1) [12,18,19,26]. The stem-loop RT primer is an
oligonucleotide that forms a stem-loop structure con-
taining a universal reverse primer sequence on the loop
and several (usually six) specific bases at 3’ end that are
complementary to the 3’end of specific mature miRNA
(Figure 1) [12]. After RT, the cDNA of miRNA can be
Table 1 Summary of commercialized qRT-PCR methods










specific universal Specific probe [54]
Stem-
loop
specific universal LNA UPL probe [32]
Poly(A) specific universal SYBR [55-57]
Poly(A) LNA specific LNA specific SYBR [58]
LNA: locked nucleic acid; UPL: Universal probe library; SYBR: SYBR Green I.
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quantitatively amplified with specific forward and uni-
versal reverse primers. The stem-loop method is able to
discriminate mature miRNAs from genomic DNA, pri-
miRNA and pre-miRNA, presumably due to the effect
of base stacking and spatial restriction of the stem-loop
RT primer [12]. In addition, a dual-labeled hydrolytic
Taqman probe that is specific for each miRNA is used
to ensure the high specificity of miRNA detection
(Figure 1A).
Initially, individual stem-loop RT primers were used for
miRNA detection. Later, pooled stem-loop RT primers
were applied for cDNA synthesis of hundreds of miRNAs
simultaneously, facilitating high-throughput miRNA pro-
filing [18,19,26]. For instance, using Megaplex Pools
(Applied Biosystems) to detect hundreds of miRNAs on
384-well plates with a compatible thermal cycler, such as
the Applied Biosystems 7900 HT, many studies identified
a number of promising biomarkers associated with can-
cers and many other diseases [24,25,27-30] (Table 2).
However, since the Taqman probes designed for this
method are distinct for each miRNA, they are likely to be
costly for global miRNAs profiling [14]. Furthermore, the
preamplification step in the stem-loop method might
cause bias in the miRNA quantification [19]. To over-
come the disadvantage of high cost while retaining the
high specificity of the stem-loop method, some research-
ers used a probe from the Universal ProbeLibrary (UPL)
for miRNA expression studies (Figure 1B) [31,32]. The
UPL probe is a class of probes produced by Roche Diag-
nostics, each of which contains 8 to 9 nucleotides with
some nucleotides modified by a locked nucleic acid
(LNA) technique. By integrating the binding sequence of
an elaborately selected UPL probe into the conventional
stem-loop RT primer, the UPL probe can be used with
the comparable specificity to the Taqman probe, result-
ing in a single probe for the economical detection of var-
ious miRNAs [31].
The poly(A) method is another means used for miRNA
expression analysis [14,33,34]. In this method, a poly(A)
tail is added to the 3’ end of each mature miRNA done
by poly(A) polymerase. Tailed miRNAs are then sub-
jected to RT using a universal RT primer containing 2 to
3 degenerate nucleotides at 3’ end followed by an oligo
(dT) and universal reverse primer sequence (Figure 2).
The synthesized cDNA is amplified with specific forward
and universal reverse primers (Figure 2A). Instead of
using a hydrolytic probe, SYBR Green I is used to quanti-
tatively detect the amplified products and provides a
more cost-effective detection method compared with the
stem-loop/Taqman probe method. However, all polyade-
nylated RNAs are possibly recognized by the oligo(dT)
RT primer. In addition, since SYBR Green I dye could
bind to all double-strand DNA including amplification
products of target miRNA, contaminant genomic DNA,
Figure 1 Schematic representation of the stem-loop method for the study of miRNA expression. The reverse transcription of miRNA can
be performed using a stem-loop RT primer that contains a universal reverse primer sequence on the loop and several specific bases at 3’ end
that are complementary to the 3’end of mature miRNA. The cDNA is amplified with specific forward and universal reverse primers. The
amplification products can be detected by either (A) specific Taqman probe or (B) universal UPL (Universal ProbeLibrary) probe.
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Table 2 Summary of circulating miRNA biomarkers identified through qRT-PCR profiling
Step 1 Step 2 Step 3 Step 4
Disease No.
Pa/Nor
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HBV: hepatitis B virus; Pa: patients; Nor: normal; N/A: not available; S: serum; P: plasma; TR: Tri-Reagent BD (Molecular Research Center or Sigma); Tz: Trizol LS reagent (Invitrogen); mir: mirVana™ miRNA isolation kit
(Ambion); AB: Megaplex™ Pools (Applied Biosystems); SBI: QuantiMir™ (System Biosciences); Severity: correlation of miRNAs expression level with disease severity; Prognosis: correlation of miRNAs expression level
and the treatment of disease; Tissue: correlation of miRNAs expression level in serum with that in tissue; Comparison: comparison between newly identified miRNA biomarkers and conventional biomarkers; ROC:
Receiver operating characteristic curve; ANOVA: Analysis of variance.



















and primer-dimers, the poly(A) method is not as specific
as the stem-loop method. Nevertheless, the specificity of
the poly(A) method can be monitored by observing the
melting curve (or dissociation curve).
Many companies, such as SBI (System Biosciences), SAB
(SABiosciences), and Invitrogen, have developed kits using
the poly(A) method for miRNA profiling (Table 1), due to
its cost-effective advantage. For example, circulating
miRNA profiling has been performed on plasma collected
from patients with colorectal cancer by using the Quanti-
Mir kit (SBI), indicating miR-17-3p and miR-92 as poten-
tial biomarkers [21] (Table 2). A modified poly(A)
method, miRCURY platform, has been developed recently
(Figure 2B, Table 1) by using enhanced LNA-specific for-
ward and reverse primers instead of a universal reverse
primer during amplification, achieving superior sensitivity
and linearity [35].
Generally, the stem-loop method has been coupled
with hydrolytic probes and the poly(A) method with
SYBR green I detection; however, these combinations
are flexible. For example, SYBR can be used in the
stem-loop method [31], and the UPL probe in the poly
(A) method [32]. Moreover, the LNA base can be
replaced by an extra artificial tail at the 5’ end of speci-
fic forward/reverse primers in the poly(A) method,
achieving considerably higher efficiency than with LNA
primers [36]. Overall, both the stem-loop and poly(A)
methods as well as their derivatives can be used in cir-
culating miRNA profiling. Currently, miRNA kits from
Applied Biosystems that use stem-loop RT primers and
Figure 2 Schematic representation of the poly(A) method used to study miRNA expression. After polyadenylation, the reverse
transcription of miRNA is carried out using a universal RT primer that contains degenerate nucleotides at 3’ end followed by an oligo(dT) and
universal reverse primer sequence. The cDNA is amplified with either (A) specific forward and universal reverse primers or (B) LNA-integrated
specific forward and specific reverse primers. The amplification products are detected by SYBR Green I.
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specific Taqman probes have the greatest popularity for
clinical miRNA evaluation.
Several controls are required for the analysis of circu-
lating miRNAs. A no-template control (NTC) can detect
the presence of primer-dimers and other non-specific
amplification products. In addition, a no-RT control
(NRC) would monitor contamination of the sample with
genomic DNA. An inter-run calibrator (IRC), usually
using a DNA fragment, is a positive control to calibrate
the deviation between qRT-PCR runs/plates. It is of
great importance to use an IRC in a profiling assay
when various samples are detected in different qRT-
PCR runs/plates. Reference controls including spike-in
RNA controls are essential for data normalization, as
discussed below.
Step 3: Data normalization and analysis
Data normalization is another major challenge for the
analysis of circulating miRNA because there are no veri-
fied housekeeping genes existing in serum/plasma that
can be used for normalization. To date, three normaliza-
tion strategies have been proposed for circulating
miRNA quantification.
The first strategy uses a stably expressed gene as a
reference control according to the existing data, such as
miR-16 [37], small nuclear/nucleolar RNAs RNU6
[21,29], RNU44 and RNU48 [38]. Although these refer-
ence genes constitute the best possible normalization
controls, they cannot ensure constant expression under
all experimental conditions [38,39]. Spiked-in RNAs,
such as cel-miR-39, cel-miR-54, and cel-miR-238, are a
class of heterogenous RNA that can not only monitor the
efficiency of RNA purification and RT, but also be used
as normalization controls [3,28,30]. By adding the same
amount of spiked-in RNAs with an equal volume of
serum/plasma, a stable reference control is obtained.
However, using an equal mass of circulating total RNA
to combine with Spike-in RNAs may result in better
accuracy for normalization.
The second strategy of data normalization is to identify
suitable normalizers for each study through the systematic
evaluation of the expression level of a set of housekeeping
genes. Several housekeeping genes are first selected and
subjected to qRT-PCR assay using a number of samples.
An algorithm named geNorm is then used to calculate the
ratio of expression level of one housekeeping gene to
another [38]; the algorithm assumes that this ratio is con-
stant across all samples. An M-value is defined as the aver-
age standard deviation of the ratio of the pairwise
housekeeping genes. The gene with the lowest M-value is
determined to have the most stable expression level. A
good combination of stably expressed housekeeping genes
can be recognized by geNorm, and the geometric average
can be used as a normalization factor for qRT-PCR data
analysis.
The geNorm program was first used to identify appro-
priate reference controls for 13 types of human tissue [38].
Later, many studies used this algorithm to successfully
identify reliable reference controls for miRNA quantifica-
tion. For example, let-7a and miR-16 were identified as
reference controls for breast cancer [40]. Similarly, miR-
191 and miR-103 were chosen as reference controls for
lung cancer and 13 distinct human solid tissues [41], as
well as circulating miR-22*, miR-26a and miR-221 for
hepatitis B virus-infected serum samples [25]. Normfinder
is another algorithm used for identification of suitable nor-
malizers [42]. The geNorm and Normfinder program have
been integrated in qRT-PCR data analysis software qBase-
plus [43,44] or GenEx [45].
It is important to identify a set of miRNAs as reference
controls; however, this procedure is labor-intensive
because of the numerous miRNAs in a number of sam-
ples that need to be measured. Additionally, there may
be few relatively stable miRNAs existing in serum/plasma
that can be chosen for conducting such a systematic eva-
luation, which limits its use in circulating miRNA quanti-
fication studies.
The third strategy is the newly reported global mean
normalization method. Instead of using a single or a set of
reference control(s), the global mean method uses the
average expression level of all miRNAs detected in a sam-
ple as a normalization factor [46]. This strategy assumes
that the mean expression level of all miRNAs in a sample,
from either the healthy control or the patient, is constant
when using the same total RNA input. Mestdagh et al.
[46] demonstrated that the global mean method was better
in reducing technical variation and preserving biological
variation than using endogenous small miRNAs, such as
nuclear/nucleolar RNAs. This method is very suitable to
normalize genome-wide miRNA profiling without the
need for selecting a specific reference control. However,
data obtained by this method should be viewed cautiously
when many miRNAs analyzed show great variability in
expression levels in a sample, since the average value in
this case will be apparently different. Moreover, the global
mean normalization method is not suitable during the bio-
marker validation (discussed in the next section) because
only few candidate miRNAs will be evaluated. The global
mean normalization program is integrated in the qBaseplus
and GenEx analysis software.
As described above, none of the three normalization
strategies provides an ideal solution for profiling circulat-
ing miRNAs. To assist analyses, the term Cq is the abbre-
viation of “quantification of cycle” recommended by the
Minimum Information for Publication of Quantitative
Real-Time PCR Experiments (MIQE), a substitution of
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the previously used terms of threshold cycle (Ct), cross-
ing point (Cp) and take off point (TOP) [47,48]. This
parameter provides an ideal reference point for the analy-
sis of qRT-PCR assays. Here, we propose a comprehen-
sive strategy. First, omit the miRNA(s) with the Cq value
difference > 5 (32-fold change) between the healthy con-
trol and the patient sample. Second, calculate the global
mean of Cq value of the extra miRNAs in each sample
(the healthy control or the patient), which is used as a
normalization factor (NF). Third, normalize all miRNAs,
including those omitted before, with the formula, ΔCq =
CqmiRNA - CqNF. Finally, calculate the fold-change
between the healthy control and patient with the for-
mula, 2-ΔΔCq [49,50]. Those miRNAs with the least fold-
changes might also be used as excellent reference con-
trols in the case studied.
Step 4: Selection and validation of miRNA biomarkers
In this step, large numbers of samples (50 to 200) are
separately used for validating the selected miRNAs in the
profiling step. Around 10 to 20 miRNAs with the greatest
fold-changes can be selected as candidate biomarkers,
each of which needs to be measured in all samples using
qRT-PCR assays. Using these analyses, only the miRNAs
that are detected in all samples can be considered candi-
date biomarkers. To identify ideal reference controls for
normalizing candidate biomarkers, approximately ten
miRNAs with the least fold-changes are also detected in
all samples. The algorithm used by the geNorm or
Normfinder programs can be used to determine the most
stable miRNAs that can serve as the normalization con-
trols. The Cq value of each candidate miRNA marker is
then normalized and transformed to the relative expres-
sion level using the formula 2-ΔCq [24]. A box plot can
then be made to present the relative expression level of
the same miRNAs found in all normal or patient samples,
with the median line showing whether a differentially-
expressed miRNA exists between the healthy and the dis-
eased samples [21,24]. The miRNA(s) with the most sig-
nificant difference in expression can then act as
promising circulating biomarkers.
Significant effort need to be performed to identify a
miRNA biomarker with clinical value for the following
reasons. First, the selected miRNA must be measured on
a more extensive scale for the determination of its clinical
applicability. Correlation between the expression level of
candidate miRNA markers and other clinical factors,
such as age, gender, severity of disease, needs to be evalu-
ated. For example, with a constant expression level dur-
ing different stages of disease, the miRNA may be a good
biomarker for the diagnosis of the early-stage disease.
However, if the expression level varies during the devel-
opment of the disease, the miRNA can serve as a useful
indicator for disease classification and prognosis [28].
Furthermore, the candidate miRNAs should be evaluated
in pathological tissue, as the abnormal miRNA expres-
sion level found in the circulation might be derived from
the release of deregulated miRNA in the tissue in the
form of microvesicles [51] or Argonaute 2 protein com-
plex [52]. This then provides a solid support for the can-
didate miRNA to be used as a biomarker if the
expression level in the circulation is similar to that in the
diseased tissue. Further analyses require blood samples
obtained from patients of pre- and post-treatment, for
example, surgical removal of carcinoma, to determine the
utility of the miRNA biomarker for prognosis.
Finally, it is necessary to detect the candidate miRNA
in other relevant diseases since many diseases may have
a similar miRNA expression pattern. For example, miR-
885-5p is elevated in liver-associated diseases encom-
passing hepatocellular carcinoma, liver cirrhosis, and
chronic hepatitis B [24]. In this case, a set of miRNA
biomarkers may provide better specificity for the diag-
nosis of each disease.
For the analyses of potential biomarkers of disease, it is
necessary to performed appropriate statistical analyses of
data obtained from the qRT-PCR assay. Generally, the
Mann-Whitney and Kruskal-Wallis tests are used for the
evaluation of the healthy control versus patient data and
among different sets of samples, respectively. However,
the Wilcoxon test is appropriate for the analysis of sam-
ples collected from the same patient over different periods
of treatment. The results that display a p-value < 0.05
represent statistically significant changes. The receiver
operating characteristic curve (ROC) can further deter-
mine whether the candidate miRNA biomarker is suffi-
ciently specific for discriminating certain type of diseased
samples from others (Table 2) [21,30].
Future directions
Although many circulating miRNAs have already been
identified as potential biomarkers, analyses including a
larger number of clinical samples are needed to validate
these selected miRNAs as effective biomarkers. More-
over, the accuracy of circulating miRNA profiling is
wholly reliant on the sample type, sample processing and
profiling method, and normalization strategy, so that the
procedure should be standardized to make the data
obtained from different labs comparable. The highest
number of circulating miRNA detected in human serum
is 368 [28], however it is unknown whether more miR-
NAs exist in the serum due to the sensitivity limit of cur-
rent techniques. Given that many miRNAs with a Cq
value of > 35 in qRT-PCR assays are frequently excluded
in the normalization step, there are presumably more
than 368 miRNAs in human serum. Thus, the develop-
ment of more sensitive and specific techniques to
increase the range of detectable miRNA in serum could
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reveal more potential biomarkers. To date, a great num-
ber of studies on circulating miRNA profiles have mainly
focused on human specimens. However, miRNA profiling
in animal is in its early stages, such as miRNA profiling
performed on cow milk using solexa sequencing [53].
Through these analyses, seven promising biomarkers
have been identified that can be used to discriminate
milk quality. Further application of qRT-PCR in animal
miRNA profiling may identify more useful biomarkers
for the diagnosis of animal diseases and quality control.
Moreover, significant reduction of the operation cost of
qRT-PCR will promote its use in animal studies.
Conclusion
The use of qRT-PCR is by far the most sensitive and
specific means for the evaluation of miRNA profiles.
Using a four-step operation of sample preparation, pro-
filing, normalization and validation, promising miRNA
biomarkers can be elucidated for clinical diagnosis and
prognosis. It is possible that the detection of circulating
miRNA biomarkers can be included in future routine
clinical examinations for the diagnosis of early stages of
diseases, such as cancer and cardiovascular disease.
Acknowledgements
This work was supported by National Natural Science Fundation of China
(grant No. 81170047) and Science Industry Trade and Information
Technology Commission of Shenzhen Municipality, China (grant No.
JC201006010725A).
Author details
1College of Life Science, Shenzhen University, Shenzhen, Guangdong,
518060, China. 2College of Animal Science and Technology, Northwest A&F
University, Yangling, Shaanxi, 712100, China.
Authors’ contributions
KK reviewed the literatures, wrote and drafted the manuscript; XP, JL and
DG revised and finalized the manuscript. All authors read and approved the
final version.
Competing interests
The authors declare that they have no competing interests.
Received: 3 January 2012 Accepted: 28 February 2012
Published: 28 February 2012
References
1. Bartel DP: MicroRNAs: target recognition and regulatory functions. Cell
2009, 136:215-233.
2. Zhang S, Chen L, Jung EJ, Calin GA: Targeting microRNAs with small
molecules: from dream to reality. Clin Pharmacol Ther 2010, 87:754-758.
3. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-
Agadjanyan EL, Peterson A, Noteboom J, O’Briant KC, Allen A, Lin DW,
Urban N, Drescher CW, Knudsen BS, Stirewalt DL, Gentleman R, Vessella RL,
Nelson PS, Martin DB, Tewari M: Circulating microRNAs as stable blood-
based markers for cancer detection. Proc Natl Acad Sci USA 2008,
105:10513-10518.
4. Brase JC, Wuttig D, Kuner R, Sultmann H: Serum microRNAs as non-
invasive biomarkers for cancer. Mol Cancer 2010, 9:306-315.
5. Yu DC, Li QG, Ding XW, Ding YT: Circulating MicroRNAs: Potential
Biomarkers for Cancer. Int J Mol Sci 2011, 12:2055-2063.
6. D’Alessandra Y, Devanna P, Limana F, Straino S, Di Carlo A, Brambilla PG,
Rubino M, Carena MC, Spazzafumo L, De Simone M, Micheli B, Biglioli P,
Achilli F, Martelli F, Maggiolini S, Marenzi G, Pompilio G, Capogrossi MC:
Circulating microRNAs are new and sensitive biomarkers of myocardial
infarction. Eur Heart J 2010, 31:2765-2773.
7. Dimmeler S, Zeiher AM: Circulating microRNAs: novel biomarkers for
cardiovascular diseases? Eur Heart J 2010, 31:2705-2707.
8. Valoczi A, Hornyik C, Varga N, Burgyan J, Kauppinen S, Havelda Z: Sensitive
and specific detection of microRNAs by northern blot analysis using
LNA-modified oligonucleotide probes. Nucleic Acids Res 2004, 32:175-183.
9. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-
Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR,
Golub TR: MicroRNA expression profiles classify human cancers. Nature
2005, 435:834-838.
10. Fichtlscherer S, De Rosa S, Fox H, Schwietz T, Fischer A, Liebetrau C,
Weber M, Hamm CW, Roxe T, Muller-Ardogan M, Bonauer A, Zeiher AM,
Dimmeler S: Circulating microRNAs in patients with coronary artery
disease. Circ Res 2010, 107:677-684.
11. Zhao H, Shen J, Medico L, Wang D, Ambrosone CB, Liu S: A pilot study of
circulating miRNAs as potential biomarkers of early stage breast cancer.
PLoS One 2010, 5:13735-13747.
12. Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, Nguyen JT, Barbisin M,
Xu NL, Mahuvakar VR, Andersen MR, Lao KQ, Livak KJ, Guegler KJ: Real-time
quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res 2005,
33:179-188.
13. Yang H, Schmuke JJ, Flagg LM, Roberts JK, Allen EM, Ivashuta S,
Gilbertson LA, Armstrong TA, Christian AT: A novel real-time polymerase
chain reaction method for high throughput quantification of small
regulatory RNAs. Plant Biotechnol J 2009, 7:621-630.
14. Benes V, Castoldi M: Expression profiling of microRNA using real-time
quantitative PCR, how to use it and what is available. Methods 2010,
50:244-249.
15. Hu Z, Chen X, Zhao Y, Tian T, Jin G, Shu Y, Chen Y, Xu L, Zen K, Zhang C,
Shen H: Serum microRNA signatures identified in a genome-wide serum
microRNA expression profiling predict survival of non-small-cell lung
cancer. J Clin Oncol 2010, 28:1721-1726.
16. Wu Q, Lu Z, Li H, Lu J, Guo L, Ge Q: Next-generation sequencing of
microRNAs for breast cancer detection. J Biomed Biotechnol 2011,
2011:597145-597152.
17. Kong W, Zhao JJ, He L, Cheng JQ: Strategies for profiling microRNA
expression. J Cell Physiol 2009, 218:22-25.
18. Tang F, Hajkova P, Barton SC, Lao K, Surani MA: MicroRNA expression
profiling of single whole embryonic stem cells. Nucleic Acids Res 2006,
34:9-16.
19. Mestdagh P, Feys T, Bernard N, Guenther S, Chen C, Speleman F,
Vandesompele J: High-throughput stem-loop RT-qPCR miRNA expression
profiling using minute amounts of input RNA. Nucleic Acids Res 2008,
36:143-151.
20. Kozomara A, Griffiths-Jones S: miRBase: integrating microRNA annotation
and deep-sequencing data. Nucleic Acids Res 2011, 39:152-157.
21. Ng EK, Chong WW, Jin H, Lam EK, Shin VY, Yu J, Poon TC, Ng SS, Sung JJ:
Differential expression of microRNAs in plasma of patients with
colorectal cancer: a potential marker for colorectal cancer screening. Gut
2009, 58:1375-1381.
22. McDonald JS, Milosevic D, Reddi HV, Grebe SK, Algeciras-Schimnich A:
Analysis of circulating microRNA: preanalytical and analytical challenges.
Clin Chem 2011, 57:833-840.
23. Kroh EM, Parkin RK, Mitchell PS, Tewari M: Analysis of circulating
microRNA biomarkers in plasma and serum using quantitative reverse
transcription-PCR (qRT-PCR). Methods 2010, 50:298-301.
24. Gui J, Tian Y, Wen X, Zhang W, Zhang P, Gao J, Run W, Tian L, Jia X, Gao Y:
Serum microRNA characterization identifies miR-885-5p as a potential
marker for detecting liver pathologies. Clin Sci (Lond) 2011, 120:183-193.
25. Zhu HT, Dong QZ, Wang G, Zhou HJ, Ren N, Jia HL, Ye QH, Qin LX:
Identification of Suitable Reference Genes for qRT-PCR Analysis of
Circulating microRNAs in Hepatitis B Virus-Infected Patients. Mol
Biotechnol 2012, 50:49-56.
26. Lao K, Xu NL, Sun YA, Livak KJ, Straus NA: Real time PCR profiling of 330
human micro-RNAs. Biotechnol J 2007, 2:33-35.
Kang et al. Journal of Animal Science and Biotechnology 2012, 3:4
http://www.jasbsci.com/content/3/1/4
Page 8 of 9
27. Resnick KE, Alder H, Hagan JP, Richardson DL, Croce CM, Cohn DE: The
detection of differentially expressed microRNAs from the serum of
ovarian cancer patients using a novel real-time PCR platform. Gynecol
Oncol 2009, 112:55-59.
28. Brase JC, Johannes M, Schlomm T, Falth M, Haese A, Steuber T,
Beissbarth T, Kuner R, Sultmann H: Circulating miRNAs are correlated with
tumor progression in prostate cancer. Int J Cancer 2011, 128:608-616.
29. Ji F, Yang B, Peng X, Ding H, You H, Tien P: Circulating microRNAs in
hepatitis B virus-infected patients. J Viral Hepat 2011, 18:242-251.
30. Zahm AM, Thayu M, Hand NJ, Horner A, Leonard MB, Friedman JR:
Circulating microRNA is a biomarker of pediatric Crohn disease. J Pediatr
Gastroenterol Nutr 2011, 53:26-33.
31. Varkonyi-Gasic E, Wu R, Wood M, Walton EF, Hellens RP: Protocol: a highly
sensitive RT-PCR method for detection and quantification of microRNAs.
Plant Methods 2007, 3:12-24.
32. Reichenstein I, Aizenberg N, Goshen M, Bentwich Z, Avni YS: A novel qPCR
assay for viral encoded microRNAs. J Virol Methods 2010, 163:323-328.
33. Shi R, Chiang VL: Facile means for quantifying microRNA expression by
real-time PCR. Biotechniques 2005, 39:519-525.
34. Zhang Y, Li M, Wang H, Fisher WE, Lin PH, Yao Q, Chen C: Profiling of 95
microRNAs in pancreatic cancer cell lines and surgical specimens by
real-time PCR analysis. World J Surg 2009, 33:698-709.
35. Jensen SG, Lamy P, Rasmussen MH, Ostenfeld MS, Dyrskjot L, Orntoft TF,
Andersen CL: Evaluation of two commercial global miRNA expression
profiling platforms for detection of less abundant miRNAs. BMC
Genomics 2011, 12:435-461.
36. Balcells I, Cirera S, Busk PK: Specific and sensitive quantitative RT-PCR of
miRNAs with DNA primers. BMC Biotechnol 2011, 11:70-81.
37. Wei J, Gao W, Zhu CJ, Liu YQ, Mei Z, Cheng T, Shu YQ: Identification of
plasma microRNA-21 as a biomarker for early detection and
chemosensitivity of non-small cell lung cancer. Chin J Cancer 2011,
30:407-414.
38. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A,
Speleman F: Accurate normalization of real-time quantitative RT-PCR
data by geometric averaging of multiple internal control genes. Genome
Biol 2002, 3:34-46.
39. Wu F, Zhang S, Dassopoulos T, Harris ML, Bayless TM, Meltzer SJ, Brant SR,
Kwon JH: Identification of microRNAs associated with ileal and colonic
Crohn’s disease. Inflamm Bowel Dis 2010, 16:1729-1738.
40. Davoren PA, McNeill RE, Lowery AJ, Kerin MJ, Miller N: Identification of
suitable endogenous control genes for microRNA gene expression
analysis in human breast cancer. BMC Mol Biol 2008, 9:76-87.
41. Peltier HJ, Latham GJ: Normalization of microRNA expression levels in
quantitative RT-PCR assays: identification of suitable reference RNA
targets in normal and cancerous human solid tissues. RNA 2008,
14:844-852.
42. Andersen CL, Jensen JL, Orntoft TF: Normalization of real-time
quantitative reverse transcription-PCR data: a model-based variance
estimation approach to identify genes suited for normalization, applied
to bladder and colon cancer data sets. Cancer Res 2004, 64:5245-5250.
43. Hellemans J, Mortier G, De Paepe A, Speleman F, Vandesompele J: qBase
relative quantification framework and software for management and
automated analysis of real-time quantitative PCR data. Genome Biol 2007,
8:19-33.
44. The qRT-PCR data analysis software qBaseplus. [http://www.biogazelle.
com/products].
45. The qRT-PCR data analysis software GenEx. [http://www.multid.se/].
46. Mestdagh P, Van Vlierberghe P, De Weer A, Muth D, Westermann F,
Speleman F, Vandesompele J: A novel and universal method for
microRNA RT-qPCR data normalization. Genome Biol 2009, 10:64-74.
47. Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, Mueller R,
Nolan T, Pfaffl MW, Shipley GL, Vandesompele J, Wittwer CT: The MIQE
guidelines: minimum information for publication of quantitative real-
time PCR experiments. Clin Chem 2009, 55:611-622.
48. Bustin SA: Why the need for qPCR publication guidelines?–The case for
MIQE. Methods 2010, 50:217-226.
49. Schmittgen TD, Livak KJ: Analyzing real-time PCR data by the
comparative C(T) method. Nat Protoc 2008, 3:1101-1108.
50. Livak KJ, Schmittgen TD: Analysis of relative gene expression data using
real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods
2001, 25:402-408.
51. Hunter MP, Ismail N, Zhang X, Aguda BD, Lee EJ, Yu L, Xiao T, Schafer J,
Lee ML, Schmittgen TD, Nana-Sinkam SP, Jarjoura D, Marsh CB: Detection
of microRNA expression in human peripheral blood microvesicles. PLoS
One 2008, 3:3694-3705.
52. Arroyo JD, Chevillet JR, Kroh EM, Ruf IK, Pritchard CC, Gibson DF,
Mitchell PS, Bennett CF, Pogosova-Agadjanyan EL, Stirewalt DL, Tait JF,
Tewari M: Argonaute2 complexes carry a population of circulating
microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci
USA 2011, 108:5003-5008.
53. Chen X, Gao C, Li H, Huang L, Sun Q, Dong Y, Tian C, Gao S, Dong H,
Guan D, Hu X, Zhao S, Li L, Zhu L, Yan Q, Zhang J, Zen K, Zhang CY:
Identification and characterization of microRNAs in raw milk during
different periods of lactation, commercial fluid, and powdered milk
products. Cell Res 2010, 20:1128-1137.
54. Applied Biosystems Megaplex™ Pools. [http://www.appliedbiosystems.
com/absite/us/en/home.html].
55. System Biosciences QuantiMir™. [http://www.systembio.com/].
56. SABiosciences RT2 miRNA PCR Array. [http://www.sabiosciences.com/].
57. Invitrogen NCode EXPRESS SYBR GreenER miRNA qRT-PCR Kit. [http://
www.invitrogen.com/site/us/en/home.html].
58. Exiqon miRCURY LNA™ Universal RT microRNA PCR. [http://www.exiqon.
com/].
doi:10.1186/2049-1891-3-4
Cite this article as: Kang et al.: Identification of circulating miRNA
biomarkers based on global quantitative real-time PCR profiling. Journal
of Animal Science and Biotechnology 2012 3:4.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Kang et al. Journal of Animal Science and Biotechnology 2012, 3:4
http://www.jasbsci.com/content/3/1/4
Page 9 of 9
